Barclays Keeps DR Horton at Equal-Weight and Cuts Target to $125
Barclays kept its equal-weight rating on DR Horton but lowered its price target to $125 from $130, according to Dow Jones Newswires, citing Benzinga data.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
Dow Jones Newswires reported that Barclays left its rating on homebuilder DR Horton unchanged at equal-weight, a neutral stance.
At the same time, the bank reduced its price target for the company's shares to $125 from $130. The information was sourced from Benzinga and timestamped 14:27 GMT.
why it matters
Analyst changes like this concern a single company and usually draw a narrow group of investors. A lower target alongside a neutral rating points to a more cautious view of DR Horton, though the broader US homebuilding market is unlikely to react much to it.
tags
instruments
sources
- DR Horton Is Maintained at Equal-Weight by Barclays — Dow Jones Newswires, 30 October 2026 at 14:27 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗